Last update : 07/09/2015 | Version : 2 | ID : 60168
General | |
Identification | |
Detailed name | Cohort of 1,000 Households for H1N1 Pandemic Follow-Up |
Sign or acronym | COPANFLU |
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CPP (IDF 1) : Réf. 09-12074 (08/09/2009); Afssaps : Réf. 2009-B90987-60 (10/09/2009); CNIl: MR001 - projet qualifié en RBM |
General Aspects | |
Medical area |
Infectious diseases |
Health determinants |
Intoxication Social and psychosocial factors |
Keywords | influenza A (H1N1), infectious respiratory syndromes, Health episodes, infections, complications, infection |
Scientific investigator(s) (Contact) | |
Name of the director | Carrat |
Surname | Fabrice |
Address | 75012 PARIS |
Phone | +33 (0)1 44 73 84 58 |
carrat@u707.jussieu.fr | |
Unit | UMR-S 707 - Épidémiologie, modélisation systèmes d'information |
Organization | Université Paris 6 et |
Name of the director | Flahault |
Surname | Antoine |
Address | 35043 RENNES |
Phone | + 33 (0)6 07 66 69 59 |
antoine.flahault@ehesp.fr | |
Unit | ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE |
Organization | EHESP |
Collaborations | |
Participation in projects, networks and consortia |
Yes |
Funding | |
Funding status |
Public |
Details | EHESP, IRD |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE - EHESP |
Organisation status |
Public |
Additional contact | |
Main features | |
Type of database | |
Type of database |
Study databases |
Study databases (details) |
Cohort study |
Database recruitment is carried out by an intermediary |
A population file |
Database recruitment is carried out as part of an interventional study |
No |
Additional information regarding sample selection. | Prospective Other bodies active in creating this cohort: INSEE Inclusion cut-off date: 01/10/2009 |
Database objective | |
Main objective | General objective: To identify individual epidemiological, environmental, immunological, social, genetic and virological risk determinants of infection by influenza A (H1N1) swine-like-(SWL) virus Secondary Objectives: - to describe the impact on public health in terms of morbidity, complications and health care resources for A (H1N1)-SWL infection; - to characterise the “natural” history of the infection and its variability, to determine how it is transmitted; - to study the individual and collective determinants of the variable clinical expressions of the infection; - to study behavioural changes induced by pandemic and assess the level of risk perception and its evolution over time; - to evaluate penetrance, application and effectiveness of control measures in place (treatment, vaccination, barriers); - to characterise the homeotypic and heterotypic immunity of participants, according to age – evaluate herd immunity and to study innate and acquired cellular immunity subsequent to infection by this virus; - To characterise viral diversity and evolutionary mechanisms of virus A (H1N1)-SWL; to study the onset of drug resistance - to build and test anticipation models in real time on the impact of pandemic on the population and to simulate different control scenarios. |
Inclusion criteria | Volunteer households in the metropolitan area whose members have all provided validated consent to participate in this cohort (Parental consent as well as children's is required, optional if they are over 7 years old and obligatory if they are over 13 years); covered by health insurance; can write and speak French and who have a land-line telephone. |
Population type | |
Age |
Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
Population covered |
General population |
Gender |
Male Woman |
Geography area |
International |
Detail of the geography area | International Study involving: Bolivia, Laos, Mali, Cameroon (not limited) Geographical area covered: National (France protocol) |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 08/2009 |
Date of last collection (YYYY or MM/YYYY) | 12/2012 |
Size of the database | |
Size of the database (number of individuals) |
[1000-10 000[ individuals |
Details of the number of individuals | 1451 |
Data | |
Database activity |
Current data collection |
Type of data collected |
Declarative data Biological data |
Declarative data (detail) |
Paper self-questionnaire Face to face interview Phone interview |
Biological data (detail) | Type of samples taken: cells samples and and serum At baseline, after possible vaccination and twice a year |
Presence of a biobank |
Yes |
Contents of biobank |
Serum DNA DNAc/RNAm |
Details of biobank content | Serum bank, DNA bank |
Health parameters studied |
Health event/morbidity Health event/mortality |
Procedures | |
Data collection method | Self-administered questionnaire: input from a paper questionnaire with double data entry Interview: input from a paper questionnaire with double data entry Biological analysis: direct input |
Participant monitoring |
Yes |
Details on monitoring of participants | Follow-up duration: 2 years |
Links to administrative sources |
Yes |
Linked administrative sources (detail) | IRIS-2000 |
Promotion and access | |
Promotion | |
Link to the document | http://www.hal.inserm.fr/COPANFLU |
Description | List of publications in HAL |
Link to the document | http://www.ncbi.nlm.nih.gov/pubmed/?term=copanflu |
Description | List of publications in Pubmed |
Access | |
Terms of data access (charter for data provision, format of data, availability delay) | According to IRESP Charter and INSERM/EHESP convention Contact Prof. Fabrice Carrat |
Access to aggregated data |
Access on specific project only |
Access to individual data |
Access on specific project only |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05